The in vitro screening partner built for industry.
Quantitative multi-endpoint assays across numerous parasite species, powered by high-throughput microscopy and custom AI software. Designed for pharmaceutical and biotech partners who need defensible, decision-grade screening data.
A modern screening pipeline, end to end.
From compound logistics to image acquisition to AI-derived phenotypes — every step is designed for throughput, reproducibility, and the kind of endpoints discovery teams actually use.
HT microscopy
Automated imaging across plate formats and life stages. Multi-well captures with consistent conditions, calibrated optics, and full chain-of-custody on samples and compounds.
Custom AI software
Computer-vision models trained on parasite and stage-specific phenotypes, including motility, viability, and development. Tuned per species for sensitivity and specificity.
Quantitative endpoints
Multi-endpoint readouts of drug action and kinetics to define dose–response (EC50/IC50) and hit calls. Complete QC visuals and exportable raw data. Reports built for discovery teams.
What we screen, and how we screen it.
Built for discovery teams.
Pharma & biotech
Hit identification, lead optimization, and back-up series screening against established and novel parasite targets.
Animal health companies
Profiling of compound libraries against species-relevant assays for livestock and companion animal pipelines.
Academic collaborators
Federally-funded research support and translational partnerships with access to live parasite material and validated assays.
Have compounds ready to profile?
Tell us about the program and we'll come back with a scoped proposal.